Dominic Rodrigues - Jun 25, 2024 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PVCT	Series D Convertible Preferred Stock	Disposed to Issuer	$0	-11.4M	-100%	$0.00^*	0	Jun 25, 2024	Common Stock	11.4M		Direct	F1, F2, F3
transaction	PVCT	Series D-1 Convertible Preferred Stock	Award	$0	+1.14M		$0.00	1.14M	Jun 25, 2024	Common Stock	11.4M		Direct	F2, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Each share of Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Convertible Preferred Stock") is convertible into one share of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F2	On June 25, 2024, 11,416,242 shares of Series D Convertible Preferred Stock held by the Reporting Person were converted into 1,141,626 shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Convertible Preferred Stock"), pursuant to that certain Conversion Agreement, dated June 21, 2024, by and between the Reporting Person and the Issuer.
F3	The Series D Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D Convertible Preferred Stock.
F4	Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's Common Stock.
F5	The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.